Procter & Gamble: Performance, Products, Pipeline and Potential

Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.


Additional Information

Procter & Gamble focuses on marketing over 300 branded products in more than 160 countries worldwide. The Health Care division develops pharmaceuticals, oral and personal health care products and is a major component of P&G’s Beauty and Health Global Business Unit.


Actonel (risedronate), a third-generation, once-daily bisphosphonate, is P&G’s only major pharmaceutical product. P&G and sanofi-aventis formed The Alliance for Better Bone Health in May 1997, to develop and market Actonel, with the companies co-promoting it in North America and in select key markets in Europe.

The Health Care division contributed 17.5 per cent of total sales in fiscal 2008, with Pharmaceuticals forming a significant proportion of Health Care revenue. However, P&G has stated that long-term focus will be concentrated on the Hair and Oral Care divisions of the Beauty and Health GBUs. The October 2005 acquisition of Gillette signalled a further deflection of focus from Pharmaceuticals and has led to a complete reorganisation of the company’s structure.

With the exception of Asacol, all of P&G’s major pharmaceutical products have lost their patent protection or face patent litigation. The launch of Roche/GlaxoSmithKline’s Boniva seems to have generated strong pressure for P&G’s flagship pharmaceutical, Actonel. Furthermore, the R&D pipeline is limited to only one in-licensed compound, pexelizumab, which failed to meet its primary endpoint in its most recent clinical trials and faces the threat of discontinuation. Actonel and Asacol should continue to generate substantial Pharmaceutical revenue, however, medium- to long-term growth will be dependent on additions to both the pipeline and product portfolio.

Learn More >>